Almac Discovery to Present at AACR 2018

April 10, 2018

Almac Discovery to Present at American Association for Cancer Research 2018

Craigavon, N.I., UK, 10 April 2018Almac Discovery, a biopharmaceutical company focused on discovering and identifying innovative therapeutics for the treatment of cancer, is pleased to announce it will present 2 posters during this year’s AACR Annual Meeting 2018 in Chicago, April 14-18.

Poster details are as follows:

Title: Accessing the cancer DUBome with UbiPlex®: A bespoke drug discovery platform for deubiquitinase enzymes

Session Category: Experimental and Molecular Therapeutics

Session Title: New Targets 1

Session Date and Time: Monday Apr 16, 2018 8:00 AM – 12:00 PM

Location: McCormick Place South, Exhibit Hall A, Poster Section 40

Poster Board Number: 10

Permanent Abstract Number: 1935

Title: Discovery and characterization of highly potent and selective USP7 inhibitors and benchmarking against clinical MDM2 antagonists

Session Category: Experimental and Molecular Therapeutics

Session Title: Novel Targets and Inhibitors

Session Date and Time: Tuesday Apr 17, 2018 1:00 PM – 5:00 PM

Location: McCormick Place South, Exhibit Hall A, Poster Section 39

Poster Board Number: 14

Permanent Abstract Number: 4869

Should you wish to meet with a representative during AACR please contact Martin Wiles, VP Business Development & Licensing – [email protected].

A copy of both posters will be made available on the Almac Discovery website immediately after the event.


Almac Discovery

Almac Discovery (a member of the Almac Group) is a research driven oncology company dedicated to the discovery and development of novel and innovative approaches to the treatment of cancer. Almac Discovery focuses on the discovery to preclinical stage seeking to licence programmes early with a pharmaceutical partner for further development.  Follow us on LinkedIn or visit

About Almac Group

‘Partnering to Advance Human Health’

The Almac Group is an established contract development and manufacturing organisation that provides an extensive range of integrated services to the pharmaceutical and biotech sectors globally. The services range from R&D, biomarker discovery development and commercialisation, API manufacture, formulation development, clinical trial supply, IXRS® technology (IVRS/IWRS) through to commercial-scale manufacture.

The international company is a privately owned organisation that has organically grown over almost 50 years and now employs close to 5600 highly skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with operations in the UK, Ireland, across the US (Pennsylvania, North Carolina and California) and in Asia (Singapore and Tokyo).


Back to news